DK0993304T3 - Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat - Google Patents

Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat

Info

Publication number
DK0993304T3
DK0993304T3 DK98925873T DK98925873T DK0993304T3 DK 0993304 T3 DK0993304 T3 DK 0993304T3 DK 98925873 T DK98925873 T DK 98925873T DK 98925873 T DK98925873 T DK 98925873T DK 0993304 T3 DK0993304 T3 DK 0993304T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
side effects
acid derivative
hydroxamic acid
reduced side
Prior art date
Application number
DK98925873T
Other languages
Danish (da)
English (en)
Inventor
Balazs Suemegi
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of DK0993304T3 publication Critical patent/DK0993304T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98925873T 1997-06-23 1998-06-22 Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat DK0993304T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9701081A HU9701081D0 (en) 1997-06-23 1997-06-23 Pharmaceutical composition of antitumoral activity
PCT/IB1998/000961 WO1998058676A1 (fr) 1997-06-23 1998-06-22 Composition pharmaceutique presentant une activite antitumorale amelioree et/ou des effets secondaires reduits contenant un agent antitumoral et un derive d'acide hydroximique

Publications (1)

Publication Number Publication Date
DK0993304T3 true DK0993304T3 (da) 2003-07-28

Family

ID=89995266

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98925873T DK0993304T3 (da) 1997-06-23 1998-06-22 Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat

Country Status (25)

Country Link
US (4) US6440998B1 (fr)
EP (1) EP0993304B1 (fr)
JP (1) JP2002508762A (fr)
KR (1) KR20010020496A (fr)
CN (1) CN1127984C (fr)
AT (1) ATE235918T1 (fr)
AU (1) AU735922B2 (fr)
BR (1) BR9810312A (fr)
CA (1) CA2294913C (fr)
CZ (1) CZ298468B6 (fr)
DE (1) DE69812949T2 (fr)
DK (1) DK0993304T3 (fr)
ES (1) ES2195344T3 (fr)
HK (1) HK1029941A1 (fr)
HU (1) HU9701081D0 (fr)
IL (1) IL133508A (fr)
NO (1) NO322206B1 (fr)
NZ (1) NZ502039A (fr)
PL (1) PL191718B1 (fr)
PT (1) PT993304E (fr)
RU (2) RU2214238C2 (fr)
SK (1) SK282877B6 (fr)
TR (1) TR199903214T2 (fr)
UA (1) UA64757C2 (fr)
WO (1) WO1998058676A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP2368554B1 (fr) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Formulations pharmaceutiques contenant de la methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
PE20130480A1 (es) * 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP3263571B2 (fr) * 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Forme cristalline de bromure de (r)-n-methylnaltrexone et utilisations associées
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
NZ584849A (en) * 2007-10-30 2012-04-27 Trophos Novel composition for treating the side effects of anticancer treatments
WO2009074835A1 (fr) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Réduction de dose d'un antagoniste des récepteurs cannabinoïdes cb1 dans le traitement d'un surpoids ou de l'obésité
CA2713568C (fr) * 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation et utilisation de (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
CN108703970A (zh) * 2013-09-18 2018-10-26 华安医学股份有限公司 一种活化ampk的化合物及其用途
RU2679136C1 (ru) * 2018-03-13 2019-02-06 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН, КНЦ СО РАН) Способ получения препарата на основе взаимодействия цис-диамин(циклобутан-1,1-дикарбоксилат-о,о')платины(ii) с арабиногалактаном
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HUT54347A (en) * 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
CZ286412B6 (en) * 1993-03-31 2000-04-12 Merck & Co Inc Synergetic combination of compounds for treating AIDS, pharmaceutical preparation containing such synergetic combination and use of this synergetic combination for preparing pharmaceutical preparation
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
IL133508A0 (en) 2001-04-30
CZ462599A3 (cs) 2000-05-17
RU2254129C2 (ru) 2005-06-20
US20020147213A1 (en) 2002-10-10
CA2294913C (fr) 2008-12-16
WO1998058676A1 (fr) 1998-12-30
BR9810312A (pt) 2000-09-19
CA2294913A1 (fr) 1998-12-30
UA64757C2 (uk) 2004-03-15
TR199903214T2 (xx) 2000-12-21
NO322206B1 (no) 2006-08-28
NZ502039A (en) 2002-03-28
HK1029941A1 (en) 2001-04-20
CN1127984C (zh) 2003-11-19
EP0993304A1 (fr) 2000-04-19
SK176499A3 (en) 2000-09-12
JP2002508762A (ja) 2002-03-19
ES2195344T3 (es) 2003-12-01
CN1263471A (zh) 2000-08-16
AU7783798A (en) 1999-01-04
US6720337B2 (en) 2004-04-13
NO996349L (no) 2000-02-23
KR20010020496A (ko) 2001-03-15
DE69812949D1 (de) 2003-05-08
PT993304E (pt) 2003-08-29
SK282877B6 (sk) 2003-01-09
PL191718B1 (pl) 2006-06-30
PL337719A1 (en) 2000-08-28
AU735922B2 (en) 2001-07-19
US6440998B1 (en) 2002-08-27
US6838469B2 (en) 2005-01-04
ATE235918T1 (de) 2003-04-15
NO996349D0 (no) 1999-12-20
CZ298468B6 (cs) 2007-10-10
HU9701081D0 (en) 1997-08-28
US20030069270A1 (en) 2003-04-10
EP0993304B1 (fr) 2003-04-02
RU2214238C2 (ru) 2003-10-20
DE69812949T2 (de) 2004-02-05
IL133508A (en) 2005-11-20
US20030050345A1 (en) 2003-03-13
US6656955B2 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
DK0993304T3 (da) Farmaceutisk sammensætning med forstærket antitumorvirkning og/eller reducerede bivirkninger, indeholdende et antitumormiddel og et hydroxamsyrederivat
FR2741066B1 (fr) Nouveaux agents de transfection et leurs applications pharmaceutiques
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
PT1123120E (pt) Formulacao medicinal em aerossol
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
CA2171275A1 (fr) Derives du stilbene et compositions pharmaceutiques qui en renferment
MD1233B1 (en) Erythromycin derivatives, process for their preparation and pharmaceutical composition on base thereof
FR2757522B1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FI832355A0 (fi) 9-(2-hydroxyetoximetyl)guanidin-derivat
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
FI962735A0 (fi) 2-hydroksi-5-fenylatsobensoehapon johdannaisten käyttö paksusuolen syövän kemialliseen ehkäisyyn ja kemoterapeuttisena aineena
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
NO20006646L (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
IL131216A0 (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
TR200002766T2 (tr) 3',3'-N-Bis-ikameli makrolit LHRH Antagonistleri
TR200002767T2 (tr) Makrolit LHRH Antagonistleri
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
ZA981079B (en) Amino acid ester containing azole antifungals.
CA2182812A1 (fr) Composition pharmaceutique pour administration transdermique systemique contenant du morphine-6-glucoronide comme principe actif
TR200102196T2 (tr) Mono-asiloksi aralkil nöromuskular relaksanları.